Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04680910 · ClinicalTrials.gov registry record · Phase 1
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
A Phase 1 study of Treatment-Resistant Depression, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04680910: Active Phase 1 study of Treatment-Resistant Depression, sponsored by Washington University School of Medicine.
NCT04680910 is a Phase 1 study of Treatment-Resistant Depression that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04680910, a Phase 1 study of Treatment-Resistant Depression, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Our hypothesis is that targeted propofol infusion in treatment-resistant depressed patients will induce slow wave activity during sedation and augment subsequent sleep slow wave activity. We will recruit 15 participants for this open label single arm Phase I trial. All participants will undergo two propofol infusions 2-6 days apart, with each infusion maximizing expression of EEG slow waves. To minimize bias, there will be no specific gender or ethnic background consideration for enrollment. This will be a single site investigation at Washington University Medical Center.
Primary Outcome
Adverse events and serious adverse events, including incidence, severity, and likelihood of relation to intervention. Evaluate whether serial propofol infusions are safe (\<5% serious adverse events directly attributable to infusions)
Conditions Studied
Interventions
- DRUG Propofol
- DIAGNOSTIC_TEST Electroencephalography (EEG)
- DIAGNOSTIC_TEST Slow-Wave Activity
Study Locations (1)
Missouri
- Washington University School of Medicine/Barnes-Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-01-14 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 1 |
What the registry record for NCT04680910 still lists
NCT04680910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 3 interventions - of which Propofol is the first listed.
NCT04680910 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04680910 about?
NCT04680910 is a clinical study titled "Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I". Our hypothesis is that targeted propofol infusion in treatment-resistant depressed patients will induce slow wave activity during sedation and augment subsequent sleep slow wave activity. We will recruit 15 participants for this open label single arm Phase I trial. All participants will undergo two ...
What is the current status of trial NCT04680910?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-01-14. Estimated completion is 2025-07-01.
What conditions does trial NCT04680910 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT04680910?
The interventions under investigation include: Propofol (DRUG), Electroencephalography (EEG) (DIAGNOSTIC_TEST), Slow-Wave Activity (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04680910?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04680910 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04680910's enrollment target sits among peer trials
15 45th of 54 higher than 9 of 54 other Treatment-Resistant Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DBS for Depression
RECRUITING · Phase 1
-
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
COMPLETED · Phase 1
-
Multiple Ascending Dose Phase 1 Study of ALA-3000
COMPLETED · Phase 1
-
Home-administered tDCS for Treatment of Depression
COMPLETED · Phase 1
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI